153 related articles for article (PubMed ID: 19777705)
1. Novel targets for therapeutic agents in small cell lung cancer.
Ma PC; Salgia R
J Natl Compr Canc Netw; 2004 Mar; 2(2):165-72. PubMed ID: 19777705
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
Xue S; Yu T; Zhang Y; Shan L
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):656-60. PubMed ID: 26483340
[TBL] [Abstract][Full Text] [Related]
4. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinases and inhibitors in lung cancer.
Pisick E; Jagadeesh S; Salgia R
ScientificWorldJournal; 2004 Aug; 4():589-604. PubMed ID: 15349502
[TBL] [Abstract][Full Text] [Related]
6. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract][Full Text] [Related]
7. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis.
Roca E; Gurizzan C; Amoroso V; Vermi W; Ferrari V; Berruti A
Cancer Treat Rev; 2017 Sep; 59():117-122. PubMed ID: 28806542
[TBL] [Abstract][Full Text] [Related]
8. MET and ALK as targets for the treatment of NSCLC.
Capelletti M; Gelsomino F; Tiseo M
Curr Pharm Des; 2014; 20(24):3914-32. PubMed ID: 24138716
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
11. [The Ras-related GTPase RhoB, a relevant actor in the adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancers].
Calvayrac O; Pradines A; Mazières J; Favre G
Med Sci (Paris); 2018 Jan; 34(1):12-14. PubMed ID: 29384086
[No Abstract] [Full Text] [Related]
12. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
Jafri NF; Ma PC; Maulik G; Salgia R
J Environ Pathol Toxicol Oncol; 2003; 22(3):147-65. PubMed ID: 14529091
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of receptor tyrosine kinases in lung cancer.
Choong NW; Ma PC; Salgia R
Expert Opin Ther Targets; 2005 Jun; 9(3):533-59. PubMed ID: 15948672
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targeted therapies in small-cell lung cancer].
Levy A; Malouf GG; Besse B; Massard C; Soria JC
Bull Cancer; 2010 May; 97(5):535-45. PubMed ID: 20093224
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.
Quintanal-Villalonga A; Paz-Ares L; Ferrer I; Molina-Pinelo S
Dis Markers; 2016; 2016():9214056. PubMed ID: 27528792
[TBL] [Abstract][Full Text] [Related]
17. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
[TBL] [Abstract][Full Text] [Related]
18. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
19. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
[TBL] [Abstract][Full Text] [Related]
20. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
